An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses

A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors

(2022) Diyuan Xue et al.   Science Immunology

Intratumoral immunotherapy relies on B and T cell collaboration

(2022) Idit Sagiv-Barfi et al.   Science Immunology

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

(2021) Golnaz Morad et al.   CELL

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

(2020) Alain P. Algazi et al.   CLINICAL CANCER RESEARCH

Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer

(2020) Mehdi Chaib et al.   Frontiers in Cell and Developmental Biology

The Immunobiology of the Interleukin-12 Family: Room for Discovery

(2019) Elia D. Tait Wojno et al.   IMMUNITY

Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy

(2019) Noor Momin et al.   Science Translational Medicine

TEMPORARY REMOVAL: IFN-γ: A cytokine at the right time, is in the right place

(2019) J. Daniel Burke et al.   SEMINARS IN IMMUNOLOGY

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

(2019) E. Antonio Chiocca et al.   Science Translational Medicine

Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells

(2018) Keunok Jung et al.   OncoImmunology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

(2018) Emmett V. Schmidt   Seminars in Immunopathology

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

(2017) Megan Lo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IgG Fc engineering to modulate antibody effector functions

(2017) Xinhua Wang et al.   Protein & Cell

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

(2016) Ji-Hee Ha et al.   Frontiers in Immunology

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

(2011) S. M. Rudman et al.   CLINICAL CANCER RESEARCH